Cache DNA, Inc., a life sciences company revolutionizing biological sample and data storage infrastructure, announced the closing of its seed round. The team raised an undisclosed amount from notable investors, including Climate Capital Bio, Exor Ventures, Hawktail, LifeX Ventures, Pillar VC, and Trousdale Ventures, including support from Illumina and...
ACTO announced the launch of TalkTRx™, the first product designed to give reps access to marketing assets with layered context so they can deliver accurate presentations and more personal with health professionals. ACTO's TalkTRx is developed as part of the company's AI-powered Intelligent Field Excellence (IFE) platform, purpose-built for...
Imaging Endpoints (IE), a global leader in Imaging CRO technologies and services, has announced the formation of a new subsidiary, Revolution Endpoints, focused on leveraging the Company's strong leadership and financial position to acquire synergistic technologies and services. This initiative aims to further advance the company's internal research programs...
ODAIA is first company to join Veeva AI Partner Program and provide industry's first GenAI solution for Veeva Vault CRM
ODAIA announced it is expanding its product partnership with Veeva Systems, joining the Veeva AI Partner Program to advance the use of Generative AI (GenAI) in life sciences. As the first product partner...
The company is introducing OM1 Orion, OM1 Lyra, and OM1 Polaris, aligning AI technology and real-world data to offer unprecedented insights into the patient journey and further patient outcomes through prediction, precision, and discovery
OM1 introduces three new products: OM1 Orion, OM1 Lyra, and OM1 Polaris powered by PhenOMTM – an artificial intelligence-powered digital phenotyping platform for personalized medicine...
QIAGEN announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services (SaaS) solution enabling high-throughput secondary analysis for use with any clinical next-generation sequencing (NGS) data.
This turnkey service supports all QIAGEN QIAseq panels and seamlessly integrates with QCI Interpret, QIAGEN’s clinical variant interpretation and reporting software, to deliver highly...
Deepcell, a pioneer in artificial intelligence (AI)-powered single cell analysis to fuel deep biological discoveries, announced the first commercial placement of the REM-I platform at Erasmus Medical Center in Rotterdam. This commercial milestone follows placements of pre-commercial instruments at laboratories in Europe and the U.S. for Beta testing. In addition,...
This end-to-end offering for bespoke RWE projects uses artificial intelligence (AI) to generate fit-for-purpose, analysis-ready clinical data sets months faster and reduces the burden on site staff
Deep 6 AI, the leader in AI-powered patient recruitment and real-world data (RWD), together with Magnolia Market Access, a provider of tailored RWD insights...
VantAI will leverage its proprietary large scale structural data and NVIDIA H100 GPUs on Google Cloud to enable a step-change in accuracy for all-atom protein interaction prediction
VantAI, a pioneer in generative AI-enabled drug discovery, is working with Google Cloud to power large scale distributed training and further improve internal...
Oncotelic Therapeutics, Inc., announced that it has entered into a binding term-sheet with Mosaic ImmunoEngineering, Inc. under which Mosaic will acquire rights to Oncotelic’s clinical-stage necroptosis cancer therapies. Oncotelic’s necroptosis therapeutics work by disrupting tumor blood flow resulting in immunogenic tumor cell death through “death receptor” activation which can...
